ahlam1399
09-14-2016, 12:21 PM
UPDATE 1-Swiss Alzheimer?s biotech AC Immune eyes $700 mln IPO valuation
Sept 14 (Reuters) - AC Immune, the Swiss biotech companyworking on treatments for Alzheimer's disease, has set thepricing band for its keenly awaited U.S. initial publicoffering, valuing the firm at about $700 million, at the top endof the range.http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=vAy6ooputfE:wDMlLPx69Gw:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=vAy6ooputfE:wDMlLPx69Gw:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=vAy6ooputfE:wDMlLPx69Gw:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=vAy6ooputfE:wDMlLPx69Gw:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=vAy6ooputfE:wDMlLPx69Gw:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/vAy6ooputfE
Sept 14 (Reuters) - AC Immune, the Swiss biotech companyworking on treatments for Alzheimer's disease, has set thepricing band for its keenly awaited U.S. initial publicoffering, valuing the firm at about $700 million, at the top endof the range.http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=vAy6ooputfE:wDMlLPx69Gw:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=vAy6ooputfE:wDMlLPx69Gw:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=vAy6ooputfE:wDMlLPx69Gw:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=vAy6ooputfE:wDMlLPx69Gw:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=vAy6ooputfE:wDMlLPx69Gw:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/vAy6ooputfE